Health

Humoral IgG1 Response Predicts Immunotherapy Outcomes

Humoral IgG1 Response Predicts Immunotherapy Outcomes - News Directory 3

PCs are enriched in clinical responders to PD-1 blockade

To test the hypothesis that ⁢B cells or PCs have a key role during immunotherapy and ⁤treatment response, we examined specimens from eight sets of self-reliant clinical trial cohorts: two newly generated datasets from our own investigator-initiated trials in patients with HCC treated with neoadjuvant PD-1 blockade, with or⁢ without‍ radiation, for discovery and validation, respectively. We also analyzed published datasets of a combination of PD-1, PD-L1, CTLA-4 and VEGF-A blockade, including large cohorts such as IMbrave150 and The Cancer Genome Atlas (TCGA) (Fig. 1a). No sex-associated differences were observed in any of the analyzed outcomes, consistent with the balanced ⁢depiction of male and⁤ female ⁤patients in the cohort.

Fig. 1: Discovery cohort and the establishment of a plasma IgG1 isotype.

a, Overview of cohorts analyzed⁤ in this study. The discovery cohort (D1) consisted of 38 patients (27 patients with HCC treated with anti-PD-1 and 11 untreated patients with HCC).Seven additional validation cohorts were included. Across all cohorts (D1 and V2), data types encompassed pretreatment and⁤ posttreatment samples from⁤ 48 in-house and 131 external patients, including bulk and single-cell RNA-seq, BCR-seq, mIHC, spatial transcriptomics, seromics (autoantibody panel), ELISpot and elisas. Certain validation cohorts included additional therapeutic contexts-for example, V7 included cabozantinib, a multi-tyrosine⁣ kinase inhibitor (TKI). b, Uniform manifold approximation and projection (UMAP) plots showing the integrated analysis of ⁤1.2 million cells from 38 patients and the reclustering of 50,000 B cells ‍and PCs. Clusters are ⁢colored⁢ by cell type/state. Annotation was based on canonical B cell and PC markers together with differentially expressed ⁣genes. c,Top,tumor enrichment scores for 27 patients,comparing tumor ⁢versus adjacent normal ‍tissue using Wilcoxon rank tests with FDR correction. Box plots ⁣show medians, ‍interquartile ranges (IQRs) (Q1-Q3), whiskers (≤1.5× IQR) and outliers.Bottom, dot plot of canonical and⁣ top ⁣differentially expressed genes per cl

JCHAIN (Fig. 1c). Naive B cells dominated ⁣the B cell fraction of the immune cells⁣ across the tissue compartments, followed by memory B cells, relative to total B cells and PCs (Extended Data Fig. 1c-f).As expected, canonical and cluster-specific genes were expressed⁣ in more ⁢than ⁣70% of cells (Extended Data Fig. 1g,h). Pathological responses to neoadjuvant PD-1 were defined as more than⁢ 50% necrosis of tumor at the time of surgery, followed‍ by differential cell abundance showing an enrichment of all PC phenotypes in the tumor among ICB responders (FDR < 0.05), which was not as pronounced in adjacent uninvolved liver (Fig. 1d,e). Conversely, non-responders were enriched in unswitched memory B cells in tumor (FDR < 0.05) but less so in normal tissues (Fig. 1d,e).

Preexisting IgG1 PCs associated with clinical response are expanded after PD-1 blockade

We⁣ hypothesized that ⁢skewing of IgG1-producing PCs is linked ‍to clinical response, given their overrepresentation in single-cell data from ‍responders (extended Data Fig. 1i). To test this, we used complementary bulk RNA-seq of paired pretreatment biopsies and posttreatment resected tumors from⁤ the discovery cohort. Principal component analysis showed that gene expression profiles were markedly ⁤diffrent between responders and non-responders (Fig.1f,g and⁢ Extended⁢ Data Fig.1j-k).

In posttreatment tumors, IGHG1 emerged as one of the top upregulated genes. Its expression was already elevated in pretreatment samples‍ from responders and increased significantly after therapy, whereas ⁤it remained unchanged or decreased⁤ in non-responders (FDR < 0.01; Fig. ⁢ 1f,g ⁢and Extended data Fig. 1j-k).

fig. 2: Clonality.
figure 2

a, Flowchart illustrating Ig isotype mapping for 37,000 single B⁤ cells, including 30,000 cells with paired BCR-seq and 7,000 additional cells mapped via gene-expression-based inference. Bottom panels show correlations between isotype ⁣assignments from gene expression and scBCR-seq⁤ for the 30,000 cells with paired data. b, Stacked bar plots showing isotype composition per sample and per patient. Multiple samples per patient were sequenced to ensure reproducibility. Single-cell BCR-seq data include six patients with HCC‍ treated with ICB (two responders and four non-responders). Using scRNA-seq-based isotype inference, the analysis was expanded to 8 responders and 14 non-responders. The y axis represents the proportion of cells (0-1). Consistent across BCR-seq and scRNA-seq-rescued⁢ isotypes, PC clusters are enriched for IgG1/IgG2, whereas naive and memory B cell clusters predominantly express IGHM and ⁢ IGHA (bottom bar plots and pie charts). c, Volcano plot ‍showing Dirichlet regression comparing responder and non-responder frequencies across clusters and isotypes ⁤(from both scRNA-seq and scBCR-seq). The log-transformed fold changes⁢ and P values were obtained from log-likelihood tests;⁢ adjusted P values were computed using Benjamini−Hochberg⁢ correction. PCs and IgG1/IgG2 responses are significantly enriched in responders. d, Box plot (as defined in Fig. 1c) showing increased IgG1+ ‍ PC representation in tumor tissue of responders ⁣with available BCR-seq. Ratios were estimated using Dirichlet regression with log-likelihood testing. e, Stacked bar plot of expanded clones per cluster, defining expansion as two or more cells per clonotype.

We examined the spatial distribution of the B cells (CD20+), PCs (MZB1+) and other immune cells in the tumor and adjacent liver in 17 mIHC biopsies (6 responders and 11 non-responders) from our discovery cohort. We observed that among anti-PD-1⁢ responders, the MZB1+ PCs were highly infiltrative⁢ throughout the tumor parenchyma compared to the PCs in non-responders (Fig. ⁤3a,b). Next,we used a radial binning approach to define cell communities or immune aggregates in an unsupervised fashion (Fig. 3c). ⁢Hear, responders showed enrichment of CD3+CD8+ T cells, CD68+ ⁣ macrophages and MZB1+ PCs. Conversely,CD20+ B cells were found ‍within the lymphoid aggregates or within the stromal compartment of the tumor rather than ⁤admixed with tumor parenchyma,reinforcing PC expansion as a hallmark of effective ICB response (Fig. 3d).

Fig. ‍3: Spatial analysis of immune infiltrating cells.a, Representative examples showing increased⁣ PC infiltration in responders compared to non-responders, quantified as the percentage of PCs within unsupervised neighborhood‍ regions derived from⁣ mIHC images. P, patient.

In ICB responders, we saw a marked enrichment of‍ IgG1+ PCs confined to an immune-rich T cell/B cell/vascular fibroblast hybrid niche,⁢ with significant upregulation of IL-4 and IL-13 signaling (Fig. 3e,f). ‍In⁤ ICB responders, we saw a marked enrichment of IgG1+ pcs confined to ⁣an immune-rich T ‍cell/B cell/vascular fibroblast hybrid ⁤niche, with significant upregulation of IL-4 and IL-13 signaling (Fig.3g,h). Pathway analysis of these clusters revealed a pro-BCR/TCR signaling⁣ hub, marked by MZB1,⁤ IL2RG, FCER2, PRDM1 ‍ and CD79A, consistent with a highly ⁢immunogenic, PC-driven microenvironment (Fig.3h,i). by contrast, non-responders harbored focal accumulations of CD27+ memory and dysfunctional B cells within ‍fibroinflammatory stromal regions. These niches were accompanied by regulatory T,T helper⁢ 17 (TH17) and monocyte signatures,collectively defining an immunosuppressive ‘stromal memory/fatigued B cell reservoir’ (fig. 3g-j).

IgG1 PCs in tumor and lymph nodes increase after radiation therapy and PD-1 checkpoint⁣ blockade

To validate these findings in an independent cohort18,we analyzed B cells and PCs from patients with HCC treated with neoadjuvant stereotactic radiation followed ‍by anti-PD-1 therapy (biopsy,lymph node,tumor and⁢ adjacent normal) (Fig.1a and⁢ Extended Data ⁢Fig. 3a-c). In bulk sequencing, differential gene expression between responders and non-responders was most⁣ pronounced in pretreatment biopsies and posttreatment tumors but minimal in lymph nodes and adjacent normal ⁤tissues (Extended Data Fig. 3d-h). After treatment, total immunoglobulin increased, with responders showing selective IgG1 enrichment⁤ (Extended Data ⁤Fig. <

V2 cohort (radiation + anti-PD-1): a,b, Differential expression analysis of adjacent normal and tumor tissues revealed IGHG1 as⁣ the ‍most significant gene associated with response, using a two-sided moderated t*-test. c, Tumor heavy-chain isotype composition by cell cluster ⁤showed *IGHG1 enrichment in responders.⁤ d, Differential abundance⁣ model.

PCs of responders (Fig. 4i-k and Extended Data Fig.5e). Next, we validated our findings in advanced HCC treated with anti-PD-1 and anti-VEGF-A therapies in two independent cohorts of unresectable HCC: IMbrave150 (ref. 20) and Cappuyns et al.21 (Fig. 4l,m).In both datasets, responders exhibited a⁤ skewing toward⁢ the IgG1 isotype, with ‍IgG1 emerging as the dominant subclass. Another independent cohort of patients with HCC and intrahepatic cholangiocarcinoma⁤ (ICCA)22 showed that HCC tumors had a low tumor diversity score, linked to favorable outcomes, whereas ICCA ⁢tumors exhibited a high tumor diversity score, linked to a more aggressive phenotype and worse outcomes (6-month survival⁤ for ICCA versus 26-month survival ⁢for HCC).Notably, ‍HCC samples had⁢ greater PC abundance, consistent with better progression-free survival in HCC than in ⁣ICCA (Fig. 4n,o). Together, these findings suggest that IgG1 PCs⁤ are⁤ strongly linked to ICB ⁤response.

ICB responders produce IgG antibodies‍ against cancer antigens

Given the enrichment ‍of IgG1 PCs in ICB responders, we explored whether ⁣theseb, Pie chart and bar plots showing that antibodies against cancer-associated ⁤antigens are predominantly enriched in responders compared to non-responders, respectively.c,d, ELISpot analysis⁢ of IFNγ-secreting cells in response to varying effector-to-target (E:T) ratios. The left panel shows wells with decreasing numbers of spots from top to bottom, corresponding to different ratios (1:1 and 5:1) for two conditions, indicating the frequency of cytokine-producing cells. The right ⁢panels represent different experimental conditions or treatments, with each row representing different⁣ replicates or conditions. Darker⁣ and more numerous spots indicate⁢ higher frequencies of cells secreting‍ IFNγ. e, Similarly, a broader⁢ characterization using seromics indicates increased abundance of autoantibodies against CTAs in responders compared to non-responders. f, Number of ⁤antigens enriched between‍ responders and ‍non-responders. g,⁤ Analysis of 16 patients (8 responders⁤ and⁣ 8 non-responders) showed that an enrichment of antibodies against CTA, tumor-associated antigen ⁤(Tu/AutoAg) ‍and other antigens was also higher ⁣in ⁣responders. Specifically, comparisons of CTA-specific IgG and ⁤IgA levels between responders and non-responders showed statistically significant differences ⁢(P = 0.04 and P = 0.01, ⁣respectively), as persistent by the Wilcoxon rank-sum test and visualized by box plots (same definition as in⁣ Fig. 1c). h, ⁣Box plots⁤ (same definition as in Fig. 1c) showing the CTA gene expression signature divided by timepoint (pre or post) and clinical response (responders and ⁢non-responders);‍ paired t-test and Wilcoxon rank test were used to estimate the ‍significance between both groups; only paired t-test results are shown in the figure. i,j, The increase⁢ in autoantibodies ⁣against CTAs in responders, specifically in the IgG1 and‍ IgA isotypes, was assessed using a heatmap⁢ to visualize relative abundance patterns across samples, violin plots to display the distribution and ⁢variability of antibody levels and quantile−quantile (Q−Q)⁢ plots to evaluate deviations from normality and highlight differences in distribution between responders and non-responders.KS, Kolmogorov–Smirnov test; NS, not significant; P/I, phorbol myristate acetate (PMA) and ionomycin positive control.

Next,to investigate T cell responses,we performed an ELISpot assay with ⁣CD8+ T cells isolated from pretreatment and on-treatment peripheral blood mononuclear cells (PBMCs),resected ‍tumors and draining lymph nodes with detectable NY-ESO-1 antibodies. The responder’s CD8+ T cells showed significant IFNγ, whereas the CD8+ T cells from the non-responder, who had predominantly IgA, showed only minimal reactivity (Fig. 5c,d). Notably, the responder ⁤had circulating NY-ESO-1 antibodies before ICB treatment, but IFNγ ‍production by CD8+ T cells was observed only in on-treatment samples, suggesting⁤ that antitumor B cell response may precede T cell response, as in previous reports23,24.

To assess if serum autoantibodies target cancer antigens more than other autoimmune targets, we performed seromic ⁢profiling (IgG and IgA against approximately 20,000 antigens, including 186 CTAs; Supplementary Table 1) on 32 paired pretreatment and posttreatment ‍samples from a discovery HCC neoadjuvant PD-1 cohort (8 responders and 8 non-responders).⁢ We observed that IgG autoantibodies and, to a lesser ⁢extent, iga were enriched for CTAs in responders compared to non-responders (Fig. 5e).

Surprisingly, reactivity to CTA was enriched for response, as antibodies detected to another‍ approximately ⁤400 other known non-CTA tumor antigens (including p53) had similar prevalence in responders and non-responders for IgG and IgA (Fig. 5f). Notably, almost all⁢ antigen-specific‍ antibodies were unique‍ to individual patients and were found before ⁤treatment and after treatment, even though some⁣ increases in ⁣reactivity were noted after⁤ treatment (Extended Data Fig.4i,j). Looking in individual samples, only CTA-specific antibodies showed a significant increase with clinical benefit in total number of reactivities (on average, 2−3 hits in responders versus 0−1 hits in non-responders) (Fig. 5g). In parallel, we did⁣ not observe ⁤correlation between gene expression of CTAs and ⁤autoantibodies, suggesting that immunogenicity is more important than expression alone (Fig. 5h). the⁣ increase in autoantibodies against CTAs in‍ responders (P < 0.05) in IgG was identified as specific for CTAs compared to iga, autoantigens and other antigens (Fig. 5i,jPlasma IgG1 ⁤signature associated with improved survival in immunotherapy

To explore ⁤the relevance of IgG1 PC expression⁢ in patient⁣ survival, we used independent immunotherapy clinical trials (approximately 1,500 patients)25,26,27. Notably, high IGHG1 expression was associated with improved overall survival in ⁤multiple datasets,⁣ including skin cutaneous melanoma (SKCM) ⁤(TCGA)25 and POPLAR26 and OAKRRBP1 Expression in Single-Cell Trajectory Analysis

The gene RRBP1 ⁣(Ribosomal ⁢RNA Binding Protein 1) exhibits a distinct ⁣expression pattern along a cellular trajectory determined⁢ by single-cell RNA sequencing and analyzed using the Monocle 3 algorithm,as indicated by pseudobulk normalized median expression plots.

Single-cell RNA sequencing allows researchers to examine gene expression ⁢in individual cells, providing a higher resolution view of‍ cellular heterogeneity than conventional bulk ‍RNA sequencing. Monocle 3 is a computational tool used to‍ infer the developmental relationships between cells, constructing a “trajectory” that represents the progression of cells ‍through different states. Pseudobulk normalization is a method used to reduce technical noise in single-cell data ⁢by grouping cells based on their trajectory position and calculating an average expression profile for each group. Moran’s I statistic is a measure of spatial autocorrelation, used here to assess the⁣ clustering of gene expression values along the‍ trajectory.

Such as, a study utilizing this methodology might reveal that ⁤ RRBP1 expression increases as cells transition from an undifferentiated state to a ‍more⁢ specialized phenotype. The‍ specific trajectory and the observed expression pattern of RRBP1 would depend ⁢on the cell type and experimental conditions‍ being studied. ⁤ Data visualization through these plots allows for the identification ⁤of genes that are dynamically regulated during cellular differentiation or response to stimuli.

CXCR4 Expression and Trajectory Correlation

The chemokine receptor CXCR4 (C-X-C Motif Chemokine Receptor 4) also demonstrates a specific expression profile along the same single-cell trajectory, visualized through pseudobulk ‍normalized median expression plots and assessed using Moran’s I.

CXCR4 plays‍ a⁢ crucial role in cell migration, ‍adhesion, and proliferation, frequently enough⁢ acting as a key regulator in developmental processes and disease progression. Analyzing ⁢its expression alongside RRBP1 can reveal potential co-regulation or functional relationships between the two genes within the context of the defined cellular trajectory.⁤ The ‍Monocle 3 algorithm helps to understand how CXCR4 expression changes as cells move through different stages of differentiation or activation.

A study ⁣might find, for instance, that CXCR4 expression is highest at a specific point along ‍the trajectory, coinciding with increased cell motility. This observation could suggest that CXCR4 is driving the cells’ movement towards a particular destination. The Moran’s⁢ I statistic would indicate whether the expression of CXCR4 ⁤ is clustered or randomly distributed along the trajectory.

ERN1 Expression as a Marker ‍of Cellular Stress

ERN1 (Endoplasmic Reticulum to Nucleus Signaling 1), a key component of the unfolded protein response (UPR), shows a distinct expression pattern ⁤along the single-cell trajectory, as visualized by pseudobulk normalized median expression plots and Moran’s I.

The UPR is activated when the ‍endoplasmic reticulum (ER) experiences stress due to an accumulation of unfolded or misfolded⁣ proteins. ERN1 is a transmembrane sensor that initiates signaling pathways to restore ER homeostasis. Its expression level can⁣ serve as an indicator of cellular stress and its ability to cope with proteotoxic challenges. Analyzing ERN1 expression in the context of a single-cell trajectory can‍ reveal ⁢how stress responses vary between individual cells.

Such as, researchers might observe that ERN1 expression increases in cells transitioning through a⁢ state of metabolic stress.This finding could indicate that these cells are experiencing ER overload and activating the UPR to mitigate the damage. The‍ Moran’s I statistic would help determine if the expression of ERN1 is spatially correlated along the trajectory, suggesting a coordinated stress response.

IGHG1 Expression and Immune Cell Differentiation

The heavy⁣ chain constant region gene IGHG1, encoding a subunit⁢ of IgG1 antibodies, exhibits a specific expression pattern along the⁣ single-cell trajectory, visualized through pseudobulk normalized ⁣median expression plots and moran’s I statistic.

IGHG1 ‍ expression is a hallmark of differentiated B cells‍ and plasma cells, ⁣responsible for producing IgG1 antibodies that mediate humoral immunity. Analyzing its expression ⁢in ⁢a ⁢single-cell trajectory can⁤ provide insights‍ into the differentiation process of B cells and the development of antibody-secreting cells. The Monocle 3 algorithm helps to map the stages of B cell development and‍ identify the factors that

Biomedicine Cancer Research General Immunology infectious diseases Metabolic Diseases Molecular Medicine Neurosciences